Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Electromedical Technologies, Inc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
Revenue
0.83
0.74
0.91
1.15
1.35
Cost of revenue
0.24
0.19
0.2
0.26
0.3
Gross profit
0.59
0.54
0.71
0.89
1.05
Research and development
0.08
0.03
0.22
0.09
0.23
Selling, general and administrative
2.26
3.71
4.51
2.49
3.11
Operating income
-1.67
-3.17
-3.8
-1.6
-2.06
Interest expense
0.05
0.77
3.31
0.79
0.89
Other non-operating income
-0.08
-0.71
-4.68
-1.86
-0.58
Net income
-1.74
-3.87
-8.48
-3.47
-2.64
EBITDA
-1.64
-3.14
-3.78
-1.58
-2.06
EPS, basic
-0.12
-0.20
-0.24
-0.03
0.00
EPS, diluted
-0.12
-0.20
-0.24
-0.03
0.00
Shares, basic (weighted)
14.3
22.3
51
134
377
Shares, diluted (weighted)
14.3
22.3
51
134
377
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
Cash and equivalents
0
0.26
0.38
0.37
0.09
Receivables
0.02
0.02
0.04
0.01
0
Inventory
0.02
0.08
0.22
0.06
0.07
Other current assets
0.07
0.29
0.04
0.21
0.29
Total current assets
0.11
0.65
0.67
0.65
0.45
Property, plant and equipment
0.77
0.75
0.73
0.71
0.15
Lease right-of-use assets
0.15
Other non-current assets
0.03
0.02
Total assets
0.9
1.42
1.4
1.35
0.75
Accounts payable
0.25
0.26
0.21
0.27
0.24
Accrued liabilities
0.19
0.04
Deferred revenue
0.04
0.03
0
0.22
0.2
Total current liabilities
2.3
2.02
1.44
2.92
3.36
Lease liabilities
0.11
Other non-current liabilities
0.01
0.02
0.01
0.01
0.01
Total liabilities
3.09
2.74
2.12
3.57
3.62
Total debt
0.73
0.7
0.67
0.15
Paid-in capital
2.71
7.96
20.8
22.2
23.8
Retained earnings
-5.25
-9.63
-21.9
-24.8
-27.5
Shareholders' equity
-2.18
-1.32
-0.72
-2.22
-2.87
Total equity
-2.18
-1.32
-0.72
-2.22
-2.87
Total liabilities and equity
0.9
1.42
1.4
1.35
0.75
Shares outstanding
15.2
27.2
87.7
190
463
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
Net income
-1.74
-3.87
-8.48
-3.47
-2.64
Depreciation and amortization
0.02
0.02
0.02
0.02
0
Stock-based compensation
0.8
2.22
2.63
0.51
0.72
Change in receivables
-0
-0.01
-0.02
0.03
0
Change in inventory
-0.05
-0.14
0.16
-0.01
Change in payables
0.08
0.01
-0.04
0.05
-0.03
Cash from operations
-0.28
-1.34
-1.19
-0.77
-1.42
Capital expenditures
-0.15
Cash from investing
1.74
Stock issued
0.11
0.01
0.04
Cash from financing
0.28
1.6
1.31
0.76
-0.61
Net change in cash
0.26
0.12
-0.01
-0.28
Free cash flow
-1.57
Interest paid
0.06
0.05
0.15
0.1
0.04
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2024; growth uses fiscal years. Valuation uses the share price of $0.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
75.1%
Gross profit / revenue.
Operating margin
-109.6%
Operating income / revenue.
EBITDA margin
-109.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-182.0%
Net income / revenue.
Operating cash flow margin
-14.2%
Cash from operations / revenue.
Return on assets (ROA)
-295.1%
Net income / average total assets.
SG&A / revenue
184.7%
Selling, general and administrative expense / revenue.
D&A / revenue
0.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
17.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
22.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
17.7%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
24.4%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-44.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-19.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
182.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
156.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.07x
Current assets / current liabilities.
Quick ratio
0.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.00
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.01
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.09x
Market cap / revenue.
EV/Sales
0.05x
Enterprise value / revenue.
Earnings yield
-1,963.0%
Net income / market cap (the inverse of P/E).
What was Electromedical Technologies, Inc's revenue in fiscal 2023?
Electromedical Technologies, Inc reported revenue of $1.3M for fiscal 2023, 17.3% higher than the year before.
Was Electromedical Technologies, Inc profitable in fiscal 2023?
No. It reported a net loss of $2.6M.
How much free cash flow did Electromedical Technologies, Inc generate in fiscal 2023?
Cash from operations of $1.4M minus capital expenditures of $149.7K left free cash flow of -$1.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.